Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) is an oncoprotein that plays a critical role in promoting tumorigenesis by inhibiting the activity of protein phosphatase 2A (PP2A), a tumor suppressor.
-CIP2A inhibits PP2A, leading to sustained activation of oncogenic signaling pathways such as AKT, MYC, and others that drive cell proliferation, survival, and growth.
-By stabilizing these oncoproteins, CIP2A contributes to tumor initiation, progression, and resistance to apoptosis.
-CIP2A is frequently overexpressed in various cancers, including breast, lung, colorectal, and head and neck cancers, among others.
-Elevated CIP2A expression promotes the malignant phenotype by deregulating key pathways that control cell cycle progression and survival.
-High CIP2A levels are generally associated with a poor prognosis. Increased expression often correlates with more aggressive tumor behavior, higher rates of metastasis, and reduced overall survival.
-In many cancer types, CIP2A overexpression is considered an independent prognostic marker, indicating a greater likelihood of treatment resistance and disease recurrence.
(Will delete Record if Target field = "Delete") Home